PSC
OSIR

Piper Sandler & Co’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History

Piper Sandler & Co’s Portfolio OSIR Stock Details OSIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-22,000
Closed -$406K – 120
2015
Q3 		$406K Buy
+22,000
New +$425K 0.43% 27
2015
Q2 		– Sell
-17,000
Closed -$299K – 155
2015
Q1 		$299K Buy
17,000
+2,000
+13% +$33.6K 0.12% 79
2014
Q4 		$240K Buy
+15,000
New +$201K 0.12% 78

Other funds holding OSIR

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
QI
QS Investors New York $8.47B AUM 30.71% 1-Year Est. Return

Piper Sandler & Co's OSIR Position: Q4 2015 in Review

Piper Sandler & Co sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q4 2015, closing a stake of 22,000 shares — an estimated $406K sold.

Piper Sandler & Co first reported a position in OSIR in Q4 2014 and held it in 3 quarters. The position peaked at $406K in Q3 2015. 81 funds tracked by Wall St. Rank hold OSIR as of Q4 2015.

  • Piper Sandler & Co reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
  • Piper Sandler & Co sold 22,000 Osiris Therapeutics, Inc. Common Stock shares in Q4 2015, an estimated $406K.
  • Piper Sandler & Co first reported a position in Osiris Therapeutics, Inc. Common Stock in Q4 2014 and held it in 3 quarters.
  • Piper Sandler & Co's Osiris Therapeutics, Inc. Common Stock position peaked at $406K in Q3 2015.
  • 81 funds tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q4 2015.

Based on Piper Sandler & Co's 13F filing for Q4 2015, filed 16 Feb 2016.